Rethinking Treatment Goals in Psoriasis: Leveraging IL-17 Inhibitors to Move Beyond Skin Clearance Toward PsA Prevention - Episode 12
Barriers to a Preventive Approach in Psoriatic Disease
In this episode, the panelists address key barriers to adopting a preventive treatment approach in psoriatic disease. The experts agree that insurance approval and prior authorization processes remain the most significant obstacles to initiating early systemic therapy. They describe the administrative challenges involved, including formulary restrictions, step therapy requirements, and the extensive time needed to secure coverage. Many dermatology practices have responded by employing biologic coordinators to handle these complex approval procedures, allowing clinicians to focus on patient care. The panelists also discuss patient-driven barriers, such as direct-to-consumer advertising that influences medication requests, and cases where patients seek drugs inappropriate for their specific disease subtype. Through these examples, the experts highlight how both system-level hurdles and patient perceptions can delay optimal therapy. They emphasize the importance of advocacy, education, and workflow support to overcome these barriers and enable earlier, prevention-focused management of psoriatic disease.
In this episode, the panelists address key barriers to adopting a preventive treatment approach in psoriatic disease. The experts agree that insurance approval and prior authorization processes remain the most significant obstacles to initiating early systemic therapy. They describe the administrative challenges involved, including formulary restrictions, step therapy requirements, and the extensive time needed to secure coverage. Many dermatology practices have responded by employing biologic coordinators to handle these complex approval procedures, allowing clinicians to focus on patient care. The panelists also discuss patient-driven barriers, such as direct-to-consumer advertising that influences medication requests, and cases where patients seek drugs inappropriate for their specific disease subtype. Through these examples, the experts highlight how both system-level hurdles and patient perceptions can delay optimal therapy. They emphasize the importance of advocacy, education, and workflow support to overcome these barriers and enable earlier, prevention-focused management of psoriatic disease.
